证券代码：603127 证券简称：昭衍新药 公告编号：2024-049 北京昭衍新药研究中心股份有限公司 关于变更公司注册资本并修订公司章程的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 综上，公司的总股份由 535,678,676 股变更为 749,477,334 股，注册资本由 535,678,676 元变更为 749,477,334 元。 由于公司实施资本公积转增股份以及股权激励等因素的影响，公司的总股份 相应发生变化。具体变化如下： 2023 年 7 月，公司回购注销了受 2019 年与 2021 年股权激励限制性股票激 励对象离职与业绩考核不达标等原因失效的 34,401 股限制性股票。注销完成后， 公司总股本由 535,678,676 股减少至 535,644,275 股，注册资本由 535,678,676 元 变更为 535,644,275 元； 2023 年 7 月，公司实施了 2022 年年度利润分配方案，除每股派发现金红利 0.40 元外，同时以资本公积金每股转增 0.4 股，即在公司总股份 535 ...

北京昭衍新药研究中心股份有限公司章程 北京昭衍新药研究中心股份有限公司 章程 二零二四年十月 1 | | 北京昭衍新药研究中心股份有限公司章程 3 | | --- | --- | | 第一章 | 总则 3 | | 第二章 | 经营宗旨和范围 4 | | 第三章 | 股份 5 | | | 第一节 股份发行 5 | | | 第二节 股份增减和回购 7 | | | 第三节 股份转让 10 | | | 第四节 购买公司股份的财务资助 12 | | | 第五节 股票和股东名册 13 | | 第四章 | 股东和股东大会 17 | | | 第一节 股东 17 | | | 第二节 股东大会的一般规定 22 | | | 第三节 股东大会的召集 25 | | | 第四节 股东大会的提案与通知 26 | | | 第五节 股东大会的召开 29 | | | 第六节 股东大会的表决和决议 33 | | | 第七节 类别股东表决的特别程序 38 | | 第五章 | 董事会 41 | | | 第一节 董事 41 | | | 第二节 董事会 45 | | | 第三节 董事会专门委员会 53 | | 第六章 | 总经理及其他高级管理人员 54 ...

证券代码：603127 证券简称：昭衍新药 公告编号：2024-048 北京昭衍新药研究中心股份有限公司 第四届董事会第十次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 北京昭衍新药研究中心股份有限公司（以下简称"公司"或"昭衍新药"）第四 届董事会第十次会议于 2024 年 10 月 16 日以书面送达、电子邮件等方式发出会 议通知，并于 2024 年 10 月 30 日在公司会议室以现场会议和电话会议的形式召 开。本次会议应参加董事 9 人，实际参加董事 9 人，会议由董事长冯宇霞女士主 持；公司全部监事和部分高级管理人员列席会议。会议的召集和召开及表决符合 《中华人民共和国公司法》和《北京昭衍新药研究中心股份有限公司章程》（以 下简称"《公司章程》"）的规定，会议程序合法、有效。 本次会议经与会董事认真审议，以举手表决方式作出了如下决议： 1.审议通过《关于公司 2024 年第三季度报告的议案》 根据《公司法》《公司章程》等规定，经公司股东提名、董事会提名委员会 资格审核，董事会同意补选罗樨女士为公司第四 ...

Financial Performance - Revenue for Q3 2024 was RMB 485,799,506.29, a decrease of 15.51% compared to the same period last year[2] - Net profit attributable to shareholders for Q3 2024 was RMB 99,435,565.54, down 58.04% year-on-year[2] - Net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2024 was RMB 84,926,745.33, a decline of 63.74% compared to the previous year[2] - Year-to-date net profit attributable to shareholders was RMB -70,307,075.11, a decrease of 121.46% compared to the same period last year[2] - Year-to-date revenue was RMB 1,335,156,050.40, down 15.87% year-on-year[2] - Basic earnings per share for Q3 2024 was RMB 0.13, a decrease of 59.38% compared to the same period last year[3] - The net profit for Q3 2024 was -74,244,009.94 RMB, a significant decrease compared to the net profit of 326,197,002.65 RMB in Q3 2023, representing a decline of approximately 122.7%[22] - Operating profit for Q3 2024 was -69,661,013.72 RMB, compared to an operating profit of 392,084,940.00 RMB in the same period last year, indicating a substantial drop[22] - Total operating revenue for the first three quarters of 2024 was CNY 1,335,156,050.40, a decrease of 15.8% compared to CNY 1,587,079,779.38 in the same period of 2023[20] - The total comprehensive income for Q3 2024 was -79,103,195.69 RMB, compared to 336,381,200.67 RMB in Q3 2023, indicating a decline of approximately 123.5%[23] Assets and Liabilities - Total assets at the end of the reporting period were RMB 9,525,184,807.98, a decrease of 5.01% from the end of the previous year[3] - Total assets amounted to CNY 9,525,184,807.98, down from CNY 10,027,159,630.47, a decrease of 5.0%[19] - Total liabilities decreased to CNY 1,534,350,209.75 from CNY 1,746,119,215.39, a reduction of 12.1%[19] - The company's total equity decreased to CNY 7,990,834,598.23 from CNY 8,281,040,415.08, a decline of 3.5%[19] - Inventory decreased to CNY 1,631,793,427.45 from CNY 1,863,081,944.56, a decrease of 12.4%[18] Cash Flow - The net cash flow from operating activities year-to-date was RMB 192,325,709.34, down 57.11% year-on-year[2] - The cash flow from operating activities for the first three quarters of 2024 was 192,325,709.34 RMB, a decrease from 448,440,218.42 RMB in the same period of 2023, showing a decline of approximately 57.1%[24] - The total cash inflow from investment activities for the first three quarters of 2024 was 2,508,098,115.21 RMB, a significant increase from 528,639,464.14 RMB in the same period of 2023[24] - The net cash flow from investing activities was -950,050,766.71, compared to -137,147,755.87 in the previous period, indicating a significant increase in cash outflow for investments[25] - The total cash outflow from financing activities was 248,828,091.97, down from 333,289,197.75 in the previous period, reflecting a reduction in financing costs[25] - The net increase in cash and cash equivalents was -1,013,522,516.10, compared to -8,194,783.60 in the previous period, showing a substantial decline in liquidity[25] - The ending balance of cash and cash equivalents was 1,840,124,511.87, down from 2,891,274,796.93 in the previous period, indicating a decrease in available cash[25] Shareholder Information - The total number of common shareholders at the end of the reporting period was 72,246, with no preferred shareholders having voting rights[9] - The largest shareholder, Feng Yuxia, holds 167,160,633 shares, representing 22.30% of the total shares[10] - The second largest shareholder, HKSCC Nominees Limited, holds 118,974,786 shares, accounting for 15.87%[10] - The company has not reported any changes in the top 10 shareholders due to margin trading or stock lending activities during the reporting period[14] - The top 10 shareholders include several institutional investors, with the largest being a medical index fund[12] Business Operations - The contribution of laboratory service business to net profit year-to-date was RMB -1,705,100, a decline of 100.55% compared to the previous year[4] - The fair value change of biological assets resulted in a net loss of RMB 17,698,420.00 year-to-date[4] - The total new signed orders for the first three quarters amounted to approximately RMB 1.4 billion, with the total outstanding orders at approximately RMB 2.65 billion as of the report date[15] - The outstanding orders execution is influenced by various factors, and investors are advised to pay attention to investment risks[15] - The company has not disclosed any new product developments or market expansion strategies in the current report[11] - The company is focusing on expanding its market presence and enhancing its product development capabilities, although specific new products or technologies were not detailed in the report[20] Research and Development - Research and development expenses for Q3 2024 were 71,085,657.06 RMB, down from 77,639,680.27 RMB in Q3 2023, reflecting a decrease of about 8.1%[22] Accounting and Standards - The company’s financial statements are unaudited as of September 30, 2024[16] - The company has adopted new accounting standards starting in 2024, which may impact future financial reporting[26]

北京昭衍新藥研究中心股份有限公司（「本公司」及其附屬公司統稱為「本集團」） 之董事會（「董事會」）兹通告謹定於2024年10月30日（星 期 三）舉 行 董 事 會 會 議，以 考慮及通過（其 中 包 括）本集團截至2024年9月30日止九個月之第三季度業績及 其 發 佈。 承董事會命 北京昭衍新藥研究中心股份有限公司 主 席 馮宇霞 JOINN LABORATORIES (CHINA) CO., LTD. 北京昭衍新藥研究中心股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：6127） 董事會召開日期 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 中 國，北 京 2024年10月18日 於 本 公 告 日 期，本 公 司 董 事 會 包 括 主 席 兼 執 行 董 事 馮 宇 霞 女 士、執 行 董 事 左 從 林 先 生、高 大 ...

证券代码：603127 证券简称：昭衍新药 公告编号：2024-047 一、 回购股份的基本情况 北京昭衍新药研究中心股份有限公司（以下简称"公司"）于 2024 年 3 月 28 日召开第四届董事会第七次会议，审议通过了《昭衍新药关于以集中竞价交易方 式回购公司 A 股股份的议案》，同意公司以自有资金通过上海证券交易所交易系 统以集中竞价交易方式回购公司已发行的部分人民币普通股（A 股）。回购的股份 将用于股权激励或员工持股计划，回购价格不超过 28.10 元/股，回购资金总额不 低于人民币 0.5 亿元（含），不超过人民币 1 亿元（含），回购期限自公司董事会 审议通过本次回购方案之日起 12 个月内。具体内容详见公司于 2024 年 3 月 29 日 披露的《昭衍新药关于以集中竞价交易方式回购公司 A 股股份的回购报告书》（公 告编号：2024-017）。 2024 年 6 月 20 日，公司召开 2023 年年度股东大会，审议通过了《公司 2023 年度利润分配的议案》，同意公司以实施权益分派时股权登记日扣除公司回购专用 账户上已回购股份后的总股本为基数分配利润，每 10 股派发现金红利 1.6 元（ ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2024年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 北京昭衍新藥研究中心股份有限公司 呈交日期: 2024年10月7日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06127 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 118,995,206 | RMB | | 1 | RMB | | 118,995,206 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 118,995,206 | RMB | | 1 | RMB | | 118,995,206 | | 2. 股份分類 ...

Financial Performance - JOINN Laboratories reported a revenue of RMB 1.2 billion for the first half of 2024, representing a year-on-year increase of 25%[6]. - The company achieved a net profit of RMB 300 million, up 30% compared to the same period last year[6]. - Revenue for the first half of 2024 was RMB 849,357,000, a decrease of 16.1% compared to RMB 1,012,077,000 in the same period of 2023[12]. - Gross profit for the first half of 2024 was RMB 211,301,000, down 52.8% from RMB 447,799,000 in the first half of 2023[12]. - The company reported a net loss attributable to equity shareholders of RMB 169,742,000 for the first half of 2024, a decline of 287.3% compared to a profit of RMB 90,627,000 in the same period of 2023[12]. - The gross margin decreased to 24.9% in the first half of 2024 from 44.2% in the same period of 2023, a reduction of 19.3 percentage points[12]. - The company reported a net loss of RMB 172.2 million for the six months ended June 30, 2024, compared to a profit of RMB 89.5 million for the same period in 2023, resulting in a net profit margin of -20.3%[30]. - The company reported a total comprehensive loss for the six months ended June 30, 2024, was RMB 169,213 thousand, compared to a total comprehensive income of RMB 102,760 thousand in 2023[91]. Market Expansion and Strategy - JOINN Laboratories plans to expand its market presence in Southeast Asia, targeting a 20% increase in market share by 2025[6]. - The company is exploring potential acquisitions to enhance its capabilities in biopharmaceuticals, with a budget of RMB 500 million allocated for this purpose[6]. - The company aims to enhance its market share and international influence in the non-clinical pharmacology and toxicology evaluation business, focusing on expanding upstream and downstream capabilities[36]. - The company plans to improve service quality by establishing new technologies and methods, optimizing internal management systems, and expanding production capacity to maintain its market share in non-clinical research services[37]. Research and Development - The company is investing RMB 200 million in R&D for new drug development, focusing on oncology and rare diseases[6]. - The company is focusing on enhancing its R&D service capabilities and quality, leveraging AI and information technology to improve operational efficiency[13]. - The company aims to expand its upstream and downstream business capabilities and build a new drug discovery platform to enhance one-stop service levels[13]. - The company is continuously updating and improving its non-clinical safety evaluation system for innovative drugs, including new types of ADC and PROTAC drugs[19]. - The company has established a high-level technical team of over 40 people and set up laboratories in Suzhou and Beijing for drug quality research and testing[23]. Operational Efficiency - JOINN Laboratories aims to enhance operational efficiency, targeting a reduction in operational costs by 10% by the end of 2024[6]. - The company plans to enhance its project management capabilities and operational efficiency to ensure the smooth launch of new experimental facilities[37]. - The company will continue to improve its performance evaluation, training, and compensation systems to boost employee productivity and support overall strategic goals[38]. Facilities and Compliance - The construction of the Suzhou Zhaoyan Phase II facility, covering 20,000 square meters, has been completed in 2023 and is expected to be operational by early 2025, enhancing business throughput and performance growth[15]. - The company has successfully passed the FDA GLP inspection for its Beijing facility for the third time, demonstrating its compliance with international GLP operational management standards[17]. - The company is actively advancing the construction of the Guangzhou Zhaoyan Anping base to support strategic planning and business needs[15]. Shareholder Information - The board does not recommend the payment of an interim dividend for the six months ending June 30, 2024[42]. - As of June 30, 2024, the company has a total of 749,888,699 issued shares, including 630,893,493 A shares and 118,995,206 H shares[44]. - Major shareholder Mr. Zhou holds 74,725,981 A shares, representing approximately 11.84% of the A shares and 9.96% of the total shares[46]. Financial Position and Assets - Total assets as of June 30, 2024, were RMB 9,661,274,000, a decrease of 3.6% from RMB 10,027,159,000 at the end of 2023[12]. - Cash and cash equivalents as of June 30, 2024, were RMB 2,158.2 million, a decrease of 24.6% from RMB 2,862.9 million as of December 31, 2023[32]. - The company reported a total of RMB 1,843,164,000 in financial assets at fair value through profit or loss as of June 30, 2024, an increase of 92.5% from RMB 961,138,000 as of December 31, 2023[132]. Employee and Talent Management - The company has a professional service team of 2,585 members as of June 30, 2024, reflecting ongoing talent development initiatives[14]. - The company is actively applying for national and regional talent policies to ensure long-term stability of its talent pool[14]. - The company will actively recruit industry experts with overseas experience to strengthen its domestic team's international business capabilities[37]. Related Party Transactions - The company has significant related party transactions with entities controlled by major shareholders, including Shutaishen (Beijing) Biopharmaceutical Co., Ltd.[163]. - Revenue from services provided to Shuyishen Group decreased to RMB 10,385,000 for the six months ended June 30, 2024, down from RMB 31,542,000 for the same period in 2023, representing a decline of approximately 67.0%[166].

（於中華人民共和國註冊成立的股份有限公司） 股份代號：6127 2024 中期報告 目錄 | 釋義 | 2 | | --- | --- | | 技術詞彙 | 6 | | 公司資料 | 7 | | 財務概要 | 9 | | 主席報告 | 10 | | 管理層討論及分析 | 11 | | 企業管治及其他資料 | 26 | | 未經審核綜合損益及其他全面收益表 | 44 | | 未經審核綜合財務狀況表 | 46 | | 未經審核綜合權益變動表 | 48 | | 未經審核綜合現金流量表 | 50 | | 未經審核中期財務報告附註 | 51 | 釋義 於本報告內，除文義另有所指外，下列詞彙具有以下涵義。該等詞彙及其定義未必與任何業內標準定義相符，亦未必 可直接與其他在本公司相同行業內經營的公司所採用的同類詞彙比較。 | 「2018年購股權及 | 指 | 本公司於2018年2月27日採納及批准的購股權及受限制股份獎勵計劃，其主 | | --- | --- | --- | | 受限制股份獎勵計劃」 | | 要條款載於招股章程 | | 「2019年購股權及 | 指 | 本公司於2019年8月15日採納及批准的購股權及受限制股 ...

FF305 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 A | | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | 603127 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | 每股發行/出售價 (註4) | 已發行股份總數 | | 於下列日期開始時的結存(註1) | 2024年9月20日 | | 628,405,814 | 2,076,314 | | 630,482,128 | | 1). 購回股份 (股份被持作庫存股份) | | | -60,000 0.01 % | 60,000 RMB | 13.512 | | | 變動日期 2024年9月24日 | | | | | | | | 於下列 ...